Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

1
Player Avatar sugarmag23 (< 20) Submitted: 6/5/2013 11:47:30 AM : Outperform Start Price: $215.34 BIIB Score: +36.27

this company will keep coming up with a succession of innovative drugs to treat deadly diseases.

Featured Broker Partners


Advertisement